5 Okt 2016 Jahr - FDA convened a joint meeting of the Anesthetic
and Analgesic Drug Products Advisory Committee
and the Drug Safety and Risk Management to
discuss naloxone products intended for use in
the community, specifically the most appropriate
dose or doses of naloxone to reverse the effects
of life-threatening opioid overdose in all ages.
Zugefügt zum Band der Zeit:
Opioids and the FDA
Datum:
